Valuation : Geron Corporation

Market Cap 951M 820M 773M 704M 1.32B 89.82B 1.33B 9.15B 3.55B 45.92B 3.57B 3.49B 151B P/E 2026 *
-35.2x
P/E 2027 * 21.8x
Enterprise Value 951M 820M 773M 704M 1.32B 89.82B 1.33B 9.15B 3.55B 45.92B 3.57B 3.49B 151B EV / Sales 2026 *
4.02x
EV / Sales 2027 * 2.78x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+7.43%
1 week+3.92%
Current month+6.71%
1 month+24.22%
3 months+35.90%
6 months+2.58%
Current year+20.45%
1 week 1.45
Extreme 1.45
1.62
1 month 1.24
Extreme 1.24
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+7.43%+3.92%+8.16%-34.84% 951M
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+2.43%+48.66%+88.33% 64.25B
+4.21%+1.80%-12.85%+380.20% 26.54B
+1.83%-7.77%+3.17%-14.91% 25.61B
+1.30%-0.96%+32.58%-17.99% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+2.88%+4.33%+57.42%+162.82% 14.1B
+1.53%+1.49%+25.41%+196.44% 12.45B
Average +2.21%-3.83%+42.87%+177.23% 26.4B
Weighted average by Cap. +1.62%-3.01%+42.56%+154.17%

Financials

2026 *2027 *
Net sales 236M 204M 192M 175M 327M 22.32B 329M 2.27B 882M 11.41B 887M 868M 37.49B 342M 295M 278M 253M 473M 32.3B 477M 3.29B 1.28B 16.52B 1.28B 1.26B 54.25B
Net income -27.18M -23.45M -22.09M -20.13M -37.62M -2.57B -37.9M -262M -101M -1.31B -102M -99.84M -4.31B 50.14M 43.26M 40.75M 37.13M 69.4M 4.74B 69.92M 482M 187M 2.42B 188M 184M 7.96B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-09-02 US$1.590 +7.43% 26,863,951
26-09-01 US$1.480 -0.67% 7,886,442
26-08-31 US$1.490 -1.32% 7,247,301
26-08-28 US$1.510 -1.31% 7,416,982
26-08-27 US$1.530 0.00% 7,883,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.480USD
Average target price
4.250USD
Spread / Average Target
+187.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock